Sanofi Dupixent approved by USFDA for pediatric patients aged 1 to 11 years with eosinophilic esophagitis Ruchika Sharma28 Jan 2024 2:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of...
USFDA updates Sanofi Dupixent label for atopic dermatitis Ruchika Sharma18 Jan 2024 3:00 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent (dupilumab) in atopic dermatitis,...
Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline Ruchika Sharma8 Dec 2023 1:30 PM ISTNew Delhi: Sanofi said on Thursday it will focus on 12 potential blockbuster drug candidates and prioritise development in immunology, as it...
Sanofi plans to seek US nod for Dupixent as COPD treatment Ruchika Sharma28 Nov 2023 1:30 PM ISTUsing Dupixent for COPD could add billions to the French drugmaker's growth prospects.
Sanofi probed for possible market manipulation by French prosecutor: Source Ruchika Sharma9 Nov 2023 4:52 PM ISTParis: French financial prosecutors have opened a preliminary probe into drugmaker Sanofi over possible share price manipulation, a person...
Require additional efficacy data for Dupixent approval for chronic spontaneous urticaria: USFDA to Sanofi Ruchika Sharma23 Oct 2023 4:44 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.
Sanofi Dupixent sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for USFDA priority review Ruchika Sharma28 Sept 2023 2:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License...
Sanofi Dupixent gets nod in India for treatment of adults with moderate-to-severe atopic dermatitis Ruchika Sharma11 July 2023 1:12 PM ISTDupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.
Sanofi Dupixent gets European Commission nod for children aged 6 months to 5 years old with severe atopic dermatitis Ruchika Sharma22 March 2023 12:45 PM ISTDupixent is an injection administered under the skin at different injection sites.
Sanofi Dupixent application for treatment of chronic spontaneous urticaria in adults, adolescents accepted for USFDA review Ruchika Sharma7 March 2023 3:30 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.
Sanofi forecasts moderate profit growth on eczema drug Dupixent demand Ruchika Sharma4 Feb 2023 10:00 AM ISTParis: Sanofi forecast moderate earnings growth that undershot expectations, saying demand for bestselling asthma and eczema drug Dupixent...
Sanofi Dupixent gets European Commission okay to treat eosinophilic esophagitis Ruchika Sharma30 Jan 2023 4:30 PM ISTDupixent is an injection administered under the skin (subcutaneous injection) at different injection sites.
